161 related articles for article (PubMed ID: 12694163)
1. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.
Hsiao LT; Lin JT; Yu IT; Chiou TJ; Liu JH; Yen CC; Wang WS; Chen PM
Eur J Haematol; 2003 May; 70(5):282-9. PubMed ID: 12694163
[TBL] [Abstract][Full Text] [Related]
2. Possible involvement of neutrophils in a serum level increase of hepatocyte growth factor in non-Hodgkin's lymphoma.
Toyama T; Ido A; Sasak H; Maeda K; Yamashita K; Kubuki Y; Suzuki M; Matsuoka H; Tsubouchi H
Oncol Rep; 2005 Mar; 13(3):439-44. PubMed ID: 15706413
[TBL] [Abstract][Full Text] [Related]
3. Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.
Etto L; Lacerda E; Baiocchi O; Silva V; Dalboni M; Alves A; Silva M; Vettore A; Colleoni G
Leuk Lymphoma; 2008 Feb; 49(2):257-64. PubMed ID: 18231911
[TBL] [Abstract][Full Text] [Related]
4. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
Giles FJ; Vose JM; Do KA; Johnson MM; Manshouri T; Bociek G; Bierman PJ; O'Brien SM; Kantarjian HM; Armitage JO; Albitar M
Leuk Res; 2004 Jun; 28(6):595-604. PubMed ID: 15120936
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma.
Guney N; Soydinc HO; Basaran M; Bavbek S; Derin D; Camlica H; Yasasever V; Topuz E
Asian Pac J Cancer Prev; 2009; 10(4):669-74. PubMed ID: 19827892
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor.
Tanimoto S; Fukumori T; El-Moula G; Shiirevnyamba A; Kinouchi S; Koizumi T; Nakanishi R; Yamamoto Y; Taue R; Yamaguchi K; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Takahashi M; Kanayama HO
J Med Invest; 2008 Feb; 55(1-2):106-11. PubMed ID: 18319552
[TBL] [Abstract][Full Text] [Related]
8. [Analysis for clinicopathological features, therapy and prognosis of 30 elderly patients with non-Hodgkin's lymphoma].
Wang HT; Yang B; Cai LL; Ran HH; Zhang WY; Zhu HL; Yang Y; Li SX; Fan H; Chi XH; Yu RL; Zhang F; Li BL; Lin J; Zhai B; Yao SQ; Lu XC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1464-70. PubMed ID: 24370030
[TBL] [Abstract][Full Text] [Related]
9. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.
Salven P; Teerenhovi L; Joensuu H
Blood; 1999 Nov; 94(10):3334-9. PubMed ID: 10552942
[TBL] [Abstract][Full Text] [Related]
10. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor.
Blay JY; Burdin N; Rousset F; Lenoir G; Biron P; Philip T; Banchereau J; Favrot MC
Blood; 1993 Oct; 82(7):2169-74. PubMed ID: 8400266
[TBL] [Abstract][Full Text] [Related]
11. [Effect of L-Type Amino Acid Transporter 1 Expression on Clinicopathological Features and Prognosis of Non-Hodgkin's Lymphoma].
Zhao ZF; Hao XJ; Yang YM; Xu WG; Zhang YX; Yuan XH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):434-438. PubMed ID: 38660848
[TBL] [Abstract][Full Text] [Related]
12. [Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients].
Wróbel T; Mazur G; Usnarska-Zubkiewicz L; Kuliczkowski K
Pol Arch Med Wewn; 2004 Aug; 112(2):919-23. PubMed ID: 15675266
[TBL] [Abstract][Full Text] [Related]
13. Serum-soluble fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma.
Hara T; Tsurumi H; Takemura M; Goto H; Yamada T; Sawada M; Takahashi T; Moriwaki H
Am J Hematol; 2000 Aug; 64(4):257-61. PubMed ID: 10911377
[TBL] [Abstract][Full Text] [Related]
14. [Clinical staging classification of non-Hodgkin's lymphoma].
Izumi T; Ozawa K
Nihon Rinsho; 2000 Mar; 58(3):598-601. PubMed ID: 10741131
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
16. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.
Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM
Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586
[TBL] [Abstract][Full Text] [Related]
17. Decreased dickkopf-1 levels in chronic lymphocytic leukemia and increased osteopontin levels in non-Hodgkin's lymphoma at initial diagnosis: Could they be playing roles in pathogenesis?
Pamuk GE; Uyanik MS; Pamuk ON; Maden M; Tapan U
Hematology; 2015 Jun; 20(5):267-71. PubMed ID: 25271869
[TBL] [Abstract][Full Text] [Related]
18. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of serum levels of soluble CD23 and tumor necrosis factor alpha in low-grade non-Hodgkin's lymphoma.
Zinzani PL; Baccini C; Zaccaria A; Visani G; Buzzi M; Morelli A; Molinari AL; Salvucci M; Bendandi M; Rubboli D; Gherlinzoni F; Zanchini R; Tura S
Eur J Haematol; 1996 Nov; 57(5):335-40. PubMed ID: 9003473
[TBL] [Abstract][Full Text] [Related]
20. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
